Routes of
administration Oral (tablets) Molar mass 396.506 g/mol | ATC code G04BD12 (WHO) Protein binding 71% | |
Trade names Myrbetriq (US), Betanis (JP), Betmiga (EU, RU) License data EU EMA: Betmiga
US FDA: Mirabegron Pregnancy
category US: C (Risk not ruled out) Legal status UK: POM (Prescription only)
US: ℞-only
In general: ℞ (Prescription only) | ||
Mirabegron activates brown fat
Mirabegron (trade name Myrbetriq meer-BET-trick in the US and Betmiga in Europe) is a drug for the treatment of overactive bladder. It was developed by Astellas Pharma and was approved in the United States in July 2012.
Contents
Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.
Medical uses
Its primary use is in the treatment of overactive bladder.
Mirabegron has also recently been shown to activate brown fat and increase metabolism. In a small study of 15 healthy, lean men, Mirabegron was shown to increase basal heart rate, metabolic rate and blood pressure which are signs of cardiovascular stimulation.
Recently, mirabegron was shown to relax in vitro human and rabbit prostatic smooth muscle through activation of β3 adrenoceptor. The same group also showed that mirabegron promotes smooth muscle relaxation by α1 adrenergic receptor blockade.
Adverse effects
Adverse effects by incidence:
Very common (>10% incidence) adverse effects include:
Common (1–10% incidence) adverse effects include:
Rare (<1% incidence) adverse effects include: